Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every week based on clinical response and tolerability.
* **Maintenance:** Usual maintenance dose is 10-20 mg twice daily.
* **Maximum dose:** 20 mg twice daily (40 mg/day). Doses higher than 20 mg/day have not been systematically studied and may increase the risk of adverse events.
## Pediatric Dosing
* **For patients weighing 30 kg or more:**
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every week.
* **Maintenance:** Usual maintenance dose is 10-20 mg twice daily.
* **Maximum dose:** 20 mg twice daily (40 mg/day).
* **For patients weighing less than 30 kg:**
* **Initiation:** 2.5 mg twice daily.
* **Titration:** Increase dose by 2.5-5 mg every week.
* **Maintenance:** Usual maintenance dose is 5-10 mg twice daily.
* **Maximum dose:** 10 mg twice daily (20 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are available, but consider starting with a lower dose and titrating slowly.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are available, but consider starting with a lower dose and titrating slowly.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Drowsiness, somnolence, constipation, decreased appetite, aggression, irritability, fatigue, ataxia, difficulty with speech, abnormal gait.
* **Serious:** Serious skin reactions (e.g., Stevens-Johnson syndrome), withdrawal symptoms (seizures, tremor, insomnia, anxiety, confusion), respiratory depression, dependence and potential for abuse.
## Key Drug Interactions
* **Central Nervous System (CNS) Depressants:** Additive CNS depression with alcohol, opioids, other benzodiazepines, sedating antihistamines, antipsychotics, and other CNS depressants.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is metabolized by CYP2C19. While not a major substrate of CYP3A4, co-administration with strong CYP3A4 inhibitors or inducers could theoretically alter clobazam concentrations, though clinical significance is uncertain.
* **CYP2C19 Inhibitors/Inducers:** Strong CYP2C19 inhibitors (e.g., fluconazole, omeprazole) may increase clobazam concentrations. Strong CYP2C19 inducers (e.g., rifampin) may decrease clobazam concentrations.
* **Antiepileptic Drugs (AEDs):** Potential for altered efficacy of concomitant AEDs.
## Monitoring
* Monitor for seizure frequency and type.
* Monitor for signs of CNS depression (drowsiness, sedation).
* Monitor for behavioral changes (aggression, irritability).
* Monitor for signs of withdrawal upon discontinuation.
* Monitor for skin reactions.
* Monitor for drug interactions, especially with other CNS depressants or CYP2C19 modulators.
## Clinical Pearls
* Clobazam should be used as adjunctive therapy and not as monotherapy for LGS.
* It has a longer half-life than many other benzodiazepines, which may allow for less frequent dosing but also increases the risk of accumulation.
* Abrupt discontinuation can lead to severe withdrawal symptoms, including seizures. Tapering is recommended.
* Behavioral and emotional problems, including aggression and suicidal behavior, have been reported.
***
*Please verify the current prescribing information for complete details, including any updates to dosing, contraindications, or adverse effects, as this information is for educational purposes and may not be exhaustive.*
